| Psoriasis vulgaris

Cimzia vs Bryhali

Side-by-side clinical, coverage, and cost comparison for psoriasis vulgaris.

Deep comparison between: Cimzia vs Bryhali with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsBryhali has a higher rate of injection site reactions vs Cimzia based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Bryhali but not Cimzia, including UnitedHealthcare

Category

Cimzia

Bryhali

At A Glance

RouteSC injection

FrequencyEvery 2-4 weeks

ClassTNF-alpha inhibitor

RouteTopical

FrequencyDaily

ClassTopical corticosteroid

Indications

Crohn Disease
Rheumatoid Arthritis
Juvenile polyarthritis
Arthritis, Psoriatic
Ankylosing spondylitis
Non-Radiographic Axial Spondyloarthritis
Psoriasis vulgaris

Psoriasis vulgaris

Dosing

Crohn Disease 400 mg SC (two 200 mg injections) at Weeks 0, 2, and 4; maintenance 400 mg every 4 weeks.

Rheumatoid Arthritis 400 mg SC at Weeks 0, 2, and 4; then 200 mg every 2 weeks; alternatively, 400 mg every 4 weeks may be considered for maintenance.

Juvenile polyarthritis Weight-based SC dosing at Weeks 0, 2, and 4, then maintenance every 2 weeks: 100 mg loading / 50 mg maintenance (10 to <20 kg); 200 mg loading / 100 mg maintenance (20 to <40 kg); 400 mg loading / 200 mg maintenance (>=40 kg).

Arthritis, Psoriatic 400 mg SC at Weeks 0, 2, and 4; then 200 mg every 2 weeks; alternatively, 400 mg every 4 weeks may be considered for maintenance.

Ankylosing spondylitis, Non-Radiographic Axial Spondyloarthritis 400 mg SC at Weeks 0, 2, and 4; then 200 mg every 2 weeks or 400 mg every 4 weeks.

Psoriasis vulgaris 400 mg SC every 2 weeks; for patients <=90 kg, 400 mg at Weeks 0, 2, and 4 followed by 200 mg every 2 weeks may be considered.

Psoriasis vulgaris Apply a thin layer to affected areas once daily; do not exceed 8 weeks of treatment or approximately 50 g per week; discontinue when control is achieved; avoid occlusive dressings unless directed, and do not use on face, groin, or axillae.

Contraindications

History of hypersensitivity reaction to certolizumab pegol or any excipient (including angioedema, anaphylaxis, serum sickness, or urticaria)

—

Drug Interactions

1383View drug interactions

73View drug interactions

Adverse Reactions

Most common (>=8%) Upper respiratory infections (18%), rash (9%), urinary tract infections (8%)

Serious Serious infections, malignancies, heart failure, hypersensitivity reactions, hepatitis B virus reactivation, neurologic reactions, hematologic reactions, autoimmunity, immunosuppression

Postmarketing Systemic vasculitis, Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme, new or worsening psoriasis (all subtypes), lichenoid skin reaction, sarcoidosis, melanoma, Merkel cell carcinoma

Most common (>=1%) Upper respiratory tract infection, application site dermatitis, hyperglycemia

Pharmacology

Certolizumab pegol is a PEGylated Fab' fragment of a humanized anti-TNF-alpha antibody that selectively neutralizes soluble and membrane-associated human TNF-alpha, a key pro-inflammatory cytokine; it lacks an Fc region and therefore does not fix complement or cause antibody-dependent cell-mediated cytotoxicity in vitro.

Topical corticosteroid; corticosteroids play a role in cellular signaling, immune function, inflammation, and protein regulation, though the precise mechanism of action in plaque psoriasis is unknown.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Cimzia